Company Overview and News
In part 2, we discussed how China’s exponential growth has given way to a powerful consumer market that many now want a piece of. But as we are coming to realize, it is not proving to be a simple task. To read the previous section, click here.
GEC GE CHIB SIEGY GNE NYTAB CKGOY
2018-09-15 seekingalpha - 1
Drones are quickly expanding beyond their traditional strongholds of the hobbyist and the military, with new applications creating a beneficial environment for component suppliers, say Brad Slingerlend and Denny Fish, co-portfolio managers of the US-based Janus Henderson Global Technology strategy.
XLNX TXN SIEGY TEL JHG INTC MCHP
As value investors, we are always on the lookout for bargains - stocks or bonds that are trading at prices below our estimate of Fair Market Value (FMV). Both research and common sense dictate that the greater the discrepancy between price and FMV, the better it provides a higher possible margin of safety and implied upside. However, securities are often detached from their FMVs because the business is suffering, leaving investors to figure out whether the issues at hand will be minor and temporary or debilitating and permanent.
NPSNY SIEGY KGI.DB NXPI HUSKF MTLHY HPE DLTR HSE TJX MTLHF SWK 4188 BIDU ORCL KL BUD KGI KGI.DB.A WDO ASR TAP BABA 0700 AHBIF HPQ WDOFF DMLRY QCOM
Management expects the GE Power market to be stable. It is continuing to decline at about 12% per year. Electrical generation from all sources, including renewables, is declining in the developed world.
GE GEC SIEGY GNE
2018-08-07 seekingalpha - 2
With the recent synergy between Enphase and its partners, it’s clear that Enphase is growing, regardless of the negative press. Good things take time to grow, and the new management has only had about a year to turn things around, and they have. Proof of Enphase’s growth was given at the recent earnings call, so let’s look at some of the details in a positive light.
PCRFY LGEAF SPWR SIEGY CAT ENPH
The deal is a strategic move by Siemens to make it easier for developers to build applications on its MindSphere IIoT platform.
Good morning, ladies and gentlemen. Welcome to our joint press and analyst conference here in Munich today. I'm Clarissa Haller and I'm in charge of Corporate Communications at Siemens and together with my colleague, Sabine Reichel, Head of Siemens Investor Relations, we will guide you through the event this morning.
SCGLF SIEGY SCGLY GLE MENT
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET